Downregulation of miR-151-5p Contributes to Increased Susceptibility to Arrhythmogenesis during Myocardial Infarction with Estrogen Deprivation

Estrogen deficiency is associated with increased incidence of cardiovascular diseases. But merely estrogen supplementary treatment can induce many severe complications such as breast cancer. The present study was designed to elucidate molecular mechanisms underlying increased susceptibility of arrhythmogenesis during myocardial infarction with estrogen deprivation, which provides us a new target to cure cardiac disease accompanied with estrogen deprivation. We successfully established a rat model of myocardial ischemia (MI) accompanied with estrogen deprivation by coronary artery ligation and ovariectomy (OVX). Vulnerability and mortality of ventricular arrhythmias increased in estrogen deficiency rats compared to non estrogen deficiency rats when suffered MI, which was associated with down-regulation of microRNA-151-5p (miR-151-5p). Luciferase Reporter Assay demonstrated that miR-151-5p can bind to the 3′-UTR of FXYD1 (coding gene of phospholemman, PLM) and inhibit its expression. We found that the expression of PLM was increased in (OVX+MI) group compared with MI group. More changes such as down-regulation of Kir2.1/IK1, calcium overload had emerged in (OVX+MI) group compared to MI group merely. Transfection of miR-151-5p into primary cultured myocytes decreased PLM levels and [Ca2+]i, however, increased Kir2.1 levels. These effects were abolished by the antisense oligonucleotides against miR-151-5p. Co-immunoprecipitation and immunofluorescent experiments confirmed the co-localization between Kir2.1 and PLM in rat ventricular tissue. We conclude that the increased ventricular arrhythmias vulnerability in response to acute myocardial ischemia in rat is critically dependent upon down-regulation of miR-151-5p. These findings support the proposal that miR-151-5p could be a potential therapeutic target for the prevention of ischemic arrhythmias in the subjects with estrogen deficiency.

[1]  Chaoqian Xu,et al.  The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2 , 2011, Nature Medicine.

[2]  M. Esteller.  Non-coding RNAs in human disease , 2011, Nature Reviews Genetics.

[3]  Susan Wilansky,et al.  Cardiovascular disease in women. , 2011, Future cardiology.

[4]  Tao Chen,et al.  Low Doses of the Carcinogen Furan Alter Cell Cycle and Apoptosis Gene Expression in Rat Liver Independent of DNA Methylation , 2010, Environmental health perspectives.

[5]  Congxin Huang,et al.  Phospholemman modulates the gating of cardiac L-type calcium channels. , 2010, Biophysical journal.

[6]  Zhe Li,et al.  Reciprocal Repression Between MicroRNA-133 and Calcineurin Regulates Cardiac Hypertrophy: A Novel Mechanism for Progressive Cardiac Hypertrophy , 2010, Hypertension.

[7]  Ming Yao,et al.  Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA , 2010, Nature Cell Biology.

[8]  Christina Backes,et al.  A dictionary on microRNAs and their putative target pathways , 2010, Nucleic acids research.

[9]  Chaoqian Xu,et al.  Tanshinone IIA protects against sudden cardiac death induced by lethal arrhythmias via repression of microRNA‐1 , 2009, British journal of pharmacology.

[10]  Yanjie Lu,et al.  Antiarrhythmic properties of long-term treatment with matrine in arrhythmic rat induced by coronary ligation. , 2009, Biological & pharmaceutical bulletin.

[11]  Chunxiang Zhang,et al.  MicroRNA Expression Signature and the Role of MicroRNA-21 in the Early Phase of Acute Myocardial Infarction* , 2009, The Journal of Biological Chemistry.

[12]  D. Bers,et al.  Isoform Specificity of the Na/K-ATPase Association and Regulation by Phospholemman* , 2009, The Journal of Biological Chemistry.

[13]  M. Shattock.  Phospholemman: its role in normal cardiac physiology and potential as a druggable target in disease. , 2009, Current opinion in pharmacology.

[14]  Xiaoying Wang,et al.  Endogenous microRNAs induced by heat‐shock reduce myocardial infarction following ischemia–reperfusion in mice , 2008, FEBS letters.

[15]  Yi Wen Kong,et al.  How do microRNAs regulate gene expression? , 2008, Biochemical Society transactions.

[16]  Jeffrey E. Thatcher,et al.  Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis , 2008, Proceedings of the National Academy of Sciences.

[17]  Sek Won Kong,et al.  Altered microRNA expression in human heart disease. , 2007, Physiological genomics.

[18]  Jiening Xiao,et al.  Retracted: Transcriptional activation by stimulating protein 1 and post‐transcriptional repression by muscle‐specific microRNAs of IKs‐encoding genes and potential implications in regional heterogeneity of their expressions , 2007, Journal of cellular physiology.

[19]  Zhiguo Wang,et al.  Resveratrol, a natural ingredient of grape skin: antiarrhythmic efficacy and ionic mechanisms. , 2006, Biochemical and biophysical research communications.

[20]  Chaoqian Xu,et al.  Choline Produces Cytoprotective Effects Against Ischemic Myocardial Injuries: Evidence for the Role of Cardiac M3 Subtype Muscarinic Acetylcholine Receptors , 2005, Cellular Physiology and Biochemistry.

[21]  A. Tucker,et al.  Phospholemman-Phosphorylation Mediates the β-Adrenergic Effects on Na/K Pump Function in Cardiac Myocytes , 2005, Circulation research.

[22]  A. Tucker,et al.  Identification of an Endogenous Inhibitor of the Cardiac Na+/Ca2+ Exchanger, Phospholemman* , 2005, Journal of Biological Chemistry.

[23]  A. Tucker,et al.  Serine 68 of phospholemman is critical in modulation of contractility, [Ca2+]i transients, and Na+/Ca2+ exchange in adult rat cardiac myocytes. , 2005, American journal of physiology. Heart and circulatory physiology.

[24]  K. Lindblad-Toh,et al.  Systematic discovery of regulatory motifs in human promoters and 3′ UTRs by comparison of several mammals , 2005, Nature.

[25]  Yan Liu,et al.  Decreases of voltage-dependent K+ currents densities in ventricular myocytes of guinea pigs by chronic oxidant stress. , 2004, Acta pharmacologica Sinica.

[26]  G A Colditz,et al.  Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. , 2004, Preventive medicine.

[27]  A. Tucker,et al.  Effects of phospholemman downregulation on contractility and [Ca(2+)]i transients in adult rat cardiac myocytes. , 2004, American journal of physiology. Heart and circulatory physiology.

[28]  S. Nattel,et al.  Tissue‐specific expression of two human Cav1.2 isoforms under the control of distinct 5′ flanking regulatory elements , 2003, FEBS letters.

[29]  Baofeng Yang,et al.  HERG K+ channel, a regulator of tumor cell apoptosis and proliferation. , 2002, Cancer research.

[30]  K. Geering,et al.  Phospholemman (FXYD1) associates with Na,K-ATPase and regulates its transport properties , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Xueqian Zhang,et al.  Overexpression of phospholemman alters contractility and [Ca(2+)](i) transients in adult rat myocytes. , 2002, American journal of physiology. Heart and circulatory physiology.

[32]  T. Clarkson,et al.  Estrogen replacement therapy, atherosclerosis, and vascular function. , 2002, Cardiovascular research.

[33]  K. Hillan,et al.  Application of cDNA microarrays in determining molecular phenotype in cardiac growth, development, and response to injury. , 2000, Circulation.

[34]  D. Luo,et al.  Artemisinin blocks activating and slowly activating K+ current in guinea pig ventricular myocytes. , 1998, Zhongguo yao li xue bao = Acta pharmacologica Sinica.

[35]  S. Sidney,et al.  Myocardial Infarction and the Use of Estrogen and Estrogen-Progestogen in Postmenopausal Women , 1997, Annals of Internal Medicine.

[36]  Caroline S. Fox,et al.  Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women , 1992, Annals of Internal Medicine.

[37]  M. Curtis,et al.  Quantification of arrhythmias using scoring systems: an examination of seven scores in an in vivo model of regional myocardial ischaemia. , 1988, Cardiovascular research.

[38]  J. P. Lindemann.  Alpha-adrenergic stimulation of sarcolemmal protein phosphorylation and slow responses in intact myocardium. , 1986, The Journal of biological chemistry.

[39]  W. Kannel,et al.  Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. , 1986, American heart journal.

[40]  L. Jones,et al.  Identification of an endogenous protein kinase C activity and its intrinsic 15-kilodalton substrate in purified canine cardiac sarcolemmal vesicles. , 1985, The Journal of biological chemistry.

[41]  L. Jones,et al.  Isoproterenol-induced phosphorylation of a 15-kilodalton sarcolemmal protein in intact myocardium. , 1985, The Journal of biological chemistry.

[42]  G. Qiao,et al.  Increasing Intracellular calcium of guinea pig ventricular myocytes induced by platelet activating factor through IP3 pathway. , 2006, Basic & clinical pharmacology & toxicology.

[43]  A. Tucker,et al.  Phospholemman overexpression inhibits Na+-K+-ATPase in adult rat cardiac myocytes: relevance to decreased Na+ pump activity in postinfarction myocytes. , 2006, Journal of applied physiology.

[44]  Xueqian Zhang,et al.  Phospholemman modulates Na+/Ca2+ exchange in adult rat cardiac myocytes. , 2003, American journal of physiology. Heart and circulatory physiology.

[45]  G. Colditz,et al.  Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence☆☆☆ , 1991 .